1,Nauck and DAlessio; Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type2 diabetes with unmatched efectiveness regrading glycaemic control and body weight reduction.Cardiovascular Diabetology. (2022) 21:169. 2,德邦证券;减...
基于胰高血糖素样肽1受体(glucagon-like peptide-1,GLP-1R)激动剂的疗法实现了超过10%的体重减轻,并使MASH消退,但患者纤维化无显著改善。与GLP-1R不同,肝脏中胰高血糖素受体(glucagon receptor,GCGR)密集,GLP-1R/GCGR双重激动剂可能...
1,Nauck and DAlessio; Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type2 diabetes with unmatched efectiveness regrading glycaemic control and body weight reduction.Cardiovascular Diabetology. (2022) 21:169. 2,德邦证券;减重药物专题:400 亿量级黄金赛道,GLP1 类药物减重市...
资料1、LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept 资料2、The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetesl. 资料3、Targeting th...
[5]Pelle MC,et al.Role of a Dual Glucose-Dependent Insulinotropic Peptide(GIP)/Glucagon-like Peptide-1 Receptor Agonist(Twincretin)in Glycemic Control:From Pathophysiology to Treatment.Life(Basel).2021 Dec 25;12(1):29. [6]Samms RJ,Coghlan MP,Sloop KW.How may GIP enhance the therapeutic eff...
多激动剂(poly-agonist)可同时模拟多种激素的作用。临床试验已表明,一些多激动剂在治疗肥胖和2型糖尿病方面具有极好的前景,并已进入2期和3期临床试验。今年,在美国,第一种用于治疗2型糖尿病的双激动剂(dual agonist)药物已被批准上市。这种双激动剂药物结合了GLP-1和GIP(glucose-dependent insulinotropic polypeptide...
2. KUN HE, et al. 763-P - Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study. General...
The invention relates to compounds having agonist activity at the GLP-1 (glucagon- like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis...
正文共: 15685字 8图 预计阅读时间:40分钟药时代编者按 2023年11月9日,中国新药出海最新喜讯传来! 诚益生物与阿斯利康达成价值20.1亿美元独家许可协议,就心血管代谢疾病领域小分子GLP-1受体激动剂ECC5004的开…
2 GLP-1(胰高血糖素样肽-1) 胰高血糖素样肽-1(GLP-1)是一种 含30或31个氨基酸的肽激素,源自胰高血糖素原肽(proglucagon)的组织特异性翻译后加工,产生两种截短且等效的生物活性形式,GLP-1(7–36)酰胺和GLP-1(7–37)。GLP-1是一种肠促胰岛素(incretin):它通过葡萄糖依赖性方式增强胰岛素分泌,以降低血糖...